SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced that the newly FDA-approved Wegovy® pill (oral semaglutide) is ...

GoodRx reports Medicaid work requirements for adults in 40 states will begin Jan. 1, 2027, potentially causing 5 million to ...

Ahead of a winter storm predicted to affect Western North Carolina, here's what pet owners should know about keeping their ...

Every day, we see the increasing role of technology in our healthcare world. It wasn’t all that long ago that we began the transition to ...

GoodRx reports five major changes to Medicare in 2026, including a $2,100 Part D out-of-pocket limit, prior authorization for ...

Ahead of a winter storm predicted to affect South Carolina, here's what pet owners should know about keeping their furry friends safe.

Novo Nordisk’s version of Wegovy in pill form represents the first-ever oral glucagon-like peptide-1 (GLP-1) receptor agonist ...

Key Insights Significant control over GoodRx Holdings by individual investors implies that the general public has ...

Overview: GoodRx Holdings, Inc. operates by providing consumers in the United States with information and tools to compare prices and save on prescription drug purchases, with a market cap of ...

Shares of LifeMD (LFMD) and GoodRx (GDRX) traded higher in the premarket on Monday after the companies announced the availability of Novo Nordisk’s (NVO) Wegovy pill as part of their product offerings ...

Shares of GoodRx Holdings Inc. sank in after-hours trading Monday after the company, which offers tools that help consumers compare drug prices, exceeded expectations with its March-quarter results ...

GoodRx's telemedicine service offers oral semaglutide for weight loss, with initial pricing of $149 for 1.5 mg and 4 mg doses, increasing to $199 for 4 mg after April 2026. Larger doses of oral ...